Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corpor...( AURORA Ontario Dec. 16 /- Helix BioPh...),Health

AURORA, Ontario, Dec. 16 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: HBP) reports that at its Annual General Meeting held today, shareholders overwhelmingly approved all of management's proposals.

Annual General Meeting Results

All seven Board members were re-elected as directors, with the Board continuing to be constituted of:

    Donald H. Segal        Chairman of the Board and Chief Executive Officer
    Kenneth A. Cawkell     Director and Corporate Secretary
    John Docherty          Director and President
    Thomas Hodgson         Director
    Jack Kay               Director
    Gordon M. Lickrish     Director
    Slawomir Majewski      Director

KPMG LLP was re-appointed as the Company's auditor.

The shareholders also approved the Company's 2008 new Stock Option Plan. Details regarding the new plan are contained in the Company's Information Circular dated Oct. 28, 2008, filed on SEDAR at www.sedar.com.

Research & Development Update

The Company is continuing its efforts toward milestone investigational new drug application (IND) filings in the United States for L-DOS47 and Topical Interferon Alpha-2b, in its cervical dysplasia indication, by the end of its 2009 fiscal year ending July 31, 2009.

L-DOS47

Helix intends to conduct a pre-IND meeting with the FDA to confirm its North American Phase I program plans for L-DOS47. The Company expects the pre-IND meeting to occur in the beginning of the 2009 calendar year. Pending the positive outcome of the pre-IND meeting and timely success of the ongoing and remaining pre-clinical and manufacturing preparatory initiatives, the Phase I IND filing for this program is anticipated to occur sometime before the
'/>"/>